Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2019 Jul 4:1-8. doi: 10.1080/13543784.2019.1638910. [Epub ahead of print]

The NK1 receptor antagonist serlopitant for treatment of chronic pruritus.

Author information

1
a Dermatology and Neurodermatology, Center for Chronic Pruritus, Department of Dermatology , University Hospital Münster , Münster , Germany.
2
b Department of Clinical Development , Menlo Therapeutics Inc , Redwood City , CA , USA.
3
c Miami Itch Center, Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine , University of Miami , Miami , FL , USA.

Abstract

Introduction: Pruritus is a common symptom associated with several potential underlying causes, including both dermatologic and systemic diseases; it can also occur without an identifiable cause. Current treatment options are limited and most patients experience impaired quality of life. Serlopitant is a neurokinin 1 (NK1) receptor antagonist under development for the treatment of pruritus associated with various dermatologic conditions and chronic pruritus of unknown origin. Areas covered: This review describes the epidemiology and unmet needs of patients with chronic pruritus, focusing specifically on patients with prurigo nodularis, psoriatic itch, and chronic pruritus of unknown origin; the rationale for targeting the NK1 receptor for treatment of chronic pruritus; and the clinical development of serlopitant, including efficacy and safety data from completed phase II studies. Expert opinion: There is an unmet need for novel, safe, and effective therapies to treat chronic pruritus. Serlopitant has shown promising efficacy, safety, and tolerability across different patient populations, including adolescents and elderly patients. In contrast to less convenient administration options, serlopitant is a once-daily oral tablet, which is expected to facilitate compliance.

KEYWORDS:

Chronic nodular prurigo; NK receptor; chronic pruritus; neurokinin 1 receptor; prurigo nodularis; psoriasis; serlopitant

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center